

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	8078166
<b>Application Number:</b>	10598810
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1607
<b>Title of Invention:</b>	Pharmaceutical formulations
<b>First Named Inventor/Applicant Name:</b>	Adrian Brown
<b>Customer Number:</b>	20462
<b>Filer:</b>	Dara L. Dinner
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	PU60746
<b>Receipt Date:</b>	23-JUL-2010
<b>Filing Date:</b>	12-SEP-2006
<b>Time Stamp:</b>	14:11:36
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	395
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	supplementalID_5July_2010.pdf	113442 4d5aa78D29a6c3d20f6a6d39cc88f6a6c5688	no	2
<b>Warnings:</b>					
<b>Information:</b>					
2	Information Disclosure Statement (IDS) Filed (SB/08)	1449_combined_July_2010.pdf	163874 6e98385265a67c4f8bce899c33395f0034076c61d	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	EP0364060B1.pdf	993970 4b5618b7c14787d82be61158376e5f223f9652	no	13
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	EP0727205B1.pdf	54272 0d6fd598a3bb651a74db3c75daef2634857a682ca	no	8
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	EP0759303.pdf	1628129 53647408be4048fe4ff0215b392e8a3c2b5fa629	no	33
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO2005070401.pdf	2323381 44d3f8d26ce0f83601a1a5f27a24c3895d9ad5a	no	29
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	WO2006107593.pdf	1058103 1a0ee730217030d824719b52866d8c25a663307c	no	19
<b>Warnings:</b>					
<b>Information:</b>					

8	Foreign Reference	WO9624337A1.pdf	752451 67f5b74523743a3e803ced05058f6820f168a6	no	20
Warnings:					
Information:					
9	Foreign Reference	WO9733569.pdf	840395 03f0f11338687ad11682638f5554d85759f95ac	no	25
Warnings:					
Information:					
10	Foreign Reference	BE900950.pdf	1071584 130156a75db4b0551512bf6de8132d2c5cf4d29c	no	31
Warnings:					
Information:					
11	Foreign Reference	EP0211079A1.pdf	952961 39c1e6b2d209a11e066e2d210711bbe0f4b63ed	no	27
Warnings:					
Information:					
12	Foreign Reference	EP0410422.pdf	1025004 8c3c59d86f6c5f713ad876d45134339f4889	no	14
Warnings:					
Information:					
13	NPL Documents	Nakamichi_J_Drug_Delivery.pdf	831582 7bac949a5d71ee69d9fbee76fd291471a7d3bc0f	no	6
Warnings:					
Information:					
14	Foreign Reference	EP1266655A.pdf	254214 07c9fbee69420ab7c16b3cda9834a361250760ca	no	22
Warnings:					
Information:					
15	Foreign Reference	EP0228067B1.pdf	903545 13bf0ddc566a6084439400283dee9b028c1362c	no	13
Warnings:					
Information:					
16	Foreign Reference	WO9516438A1.pdf	817338 a500dbaa7f0ed696950f9eeee8b78f5ce7f68a0fb	no	27
Warnings:					
Information:					

17	Foreign Reference	WO9615775.pdf	636806 6c766e4477bbf96668c7b5bc51c387f61d3546bc	no	21
Warnings:					
Information:					
18	NPL Documents	Fukui_IntJournalPhar_Vol217_pp33_43_2001.pdf	1060135 e3ee798932632488c384c5ef6e1ebc27634ea01c5	no	12
Warnings:					
Information:					
19	NPL Documents	Kohri_IntJPharm_49_pp213_221_1989.pdf	678843 a86f6e05a9d1e110c8f903bca31c7d13053981	no	9
Warnings:					
Information:					
20	NPL Documents	Mehuys_EurJourPharSciences_Vol24_pp207_212_2005.pdf	643387 d9c4c18180e8b15d13bf9a1bdf16952b0c97279d	no	6
Warnings:					
Information:					
21	Fee Worksheet (PTO-875)	fee-info.pdf	29899 2a5e6e75e85480a6498aca182626a8f5acc09d5	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			16833315		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					